Physician profile
Morris Antebi
NPI 1578532404
$1,518.13
in general payments reported to CMS, 2019-2025
22 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.96 · 2020: $50.34 · 2021: $66.80 · 2022: $97.71 · 2023: $242 · 2024: $463 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929 · Travel and Lodging: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.12 |
| Travel and Lodging | $279.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $581.02 | 2023-2025 | Intellis Adaptivestim |
| Spr Therapeutics, INC | $159.40 | 2024 | Sprint Pns System |
| Abbott Laboratories | $101.36 | 2024 | Eterna |
| Si-Bone, INC. | $100.81 | 2020-2024 | |
| Boston Scientific Corporation | $92.50 | 2024-2025 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.99 | 2024-2025 | Relistor |
| Kowa Pharmaceuticals America, INC. | $58.68 | 2022-2023 | Seglentis |
| Grt US Holding, INC. | $55.10 | 2022 | |
| Fidia Pharma USA INC. | $47.95 | 2023 | Triluron, Hymovis, Hyalgan |
| Scilex Pharmaceuticals INC. | $45.67 | 2021-2022 | |
| Indivior INC. | $28.99 | 2019 | |
| Protega Pharmaceutials INC | $28.00 | 2023 | Roxybond |
| Nalu Medical, INC. | $17.46 | 2023 | Nalu Neurostimulation System |
| Virtus Pharmaceuticals LLC | $15.73 | 2025 | Levorphanol Tartrate |
| Novartis Pharmaceuticals Corporation | $14.79 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.66 | 2019 | |
| Averitas Pharma INC. | $13.36 | 2023 | Qutenza |
| Mdd US Operations, LLC | $12.94 | 2019 | |
| Biodelivery Sciences International, INC. | $12.74 | 2020 | |
| Orexo US, INC. | $12.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.44 | 2019 | |
| Depuy Synthes Sales INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Antebi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.